Digoxin: Na⁺/K⁺ ATPase Pump Inhibitor for Heart Failure and Antiviral Research

Executive Summary: Digoxin is a validated cardiac glycoside with high affinity for the Na⁺/K⁺-ATPase pump, leading to increased cardiac contractility and proven utility in heart failure and arrhythmia research (APExBIO). It also impairs chikungunya virus infection in human cell models at concentrations from 0.01 to 10 μM (anti-trop2.com). The compound is highly soluble in DMSO (≥33.25 mg/mL), but insoluble in water and ethanol, and is provided as a solid with >98.6% purity. Its efficacy and reproducibility in both cardiovascular and antiviral applications are supported by HPLC and NMR documentation (qpcrmaster.com). APExBIO’s QC standards enable reproducible workflows for researchers in translational and mechanistic studies.

Biological Rationale

Digoxin is a classic cardiac glycoside, originally derived from Digitalis species, and is widely used in research on cardiac contractility, arrhythmias, and heart failure (APExBIO). The drug’s primary biological rationale is its potent inhibition of the Na⁺/K⁺-ATPase pump, a critical membrane protein regulating intracellular sodium and potassium gradients. Inhibition of this pump leads to increased intracellular sodium, which in turn reduces the activity of the Na⁺/Ca²⁺ exchanger, resulting in higher intracellular calcium concentration. Elevated calcium enhances cardiac contractility—a key benefit in failing myocardium (anti-trop2.com). Beyond cardiovascular research, digoxin is gaining traction as an antiviral agent, particularly against chikungunya virus (CHIKV), by disrupting virus entry and replication in human cell lines.

Mechanism of Action of Digoxin

Digoxin binds specifically to the extracellular domain of the Na⁺/K⁺-ATPase pump in cardiac myocytes. This binding inhibits the active transport of sodium and potassium ions across the cell membrane. As intracellular sodium increases, the secondary active transport via the Na⁺/Ca²⁺ exchanger is reduced, causing accumulation of cytosolic calcium. The elevated calcium triggers stronger and more sustained contraction of cardiac muscle fibers. In animal models, intravenous digoxin (1–1.2 mg) increases cardiac output and decreases right atrial pressure, demonstrating its effect on cardiac hemodynamics (APExBIO). In antiviral research, digoxin impairs CHIKV infection in U-2 OS, primary human synovial fibroblasts, and Vero cells in a dose-dependent manner at concentrations between 0.01–10 μM (anti-trop2.com).

Evidence & Benchmarks

• Digoxin increases cardiac contractility by inhibiting the Na⁺/K⁺-ATPase pump and raising intracellular calcium in cardiac cells (DOI:10.1016/j.biopha.2025.118665).
• In canine models of congestive heart failure, intravenous digoxin (1–1.2 mg) improved cardiac output and reduced right atrial pressure under controlled laboratory conditions (APExBIO).
• Digoxin demonstrated potent inhibition of chikungunya virus infection in human cell models (U-2 OS, primary human synovial fibroblasts, Vero cells) at 0.01–10 μM in vitro (anti-trop2.com).
• High solubility in DMSO (≥33.25 mg/mL) ensures compatibility with standard laboratory protocols (qpcrmaster.com).
• Digoxin from APExBIO is validated at >98.6% purity with quality control via HPLC, NMR, and MSDS, supporting reproducible results in research applications (APExBIO).

For an in-depth technical discussion of workflow optimization and reproducibility, see this evidence-based guide, which details how APExBIO’s Digoxin ensures sensitive and safe experimental design. This article extends the discussion by providing new data on antiviral benchmarks and animal model dosing strategies.

Applications, Limits & Misconceptions

Digoxin is primarily used in preclinical research focused on:

• Cardiac contractility modulation in heart failure and arrhythmia models.
• Investigation of Na⁺/K⁺-ATPase signaling in cardiovascular disease.
• Antiviral assays, especially inhibition of chikungunya virus infection in human and primate cell lines.
• Pharmacokinetic and pharmacodynamic modeling in animal studies.

For a review detailing digoxin’s dual roles and workflow compatibility, see this overview. This current article clarifies the concentration ranges and cell models where digoxin is effective against CHIKV, providing updated antiviral efficacy data.

Common Pitfalls or Misconceptions

• Digoxin is not soluble in water or ethanol; DMSO is required for stock solutions.
• Long-term storage of digoxin solutions is not recommended; fresh preparation ensures activity.
• Not all cell lines or viral strains are equally sensitive to digoxin; efficacy should be validated for each experimental system.
• Digoxin is supplied for research use only; its clinical use requires additional regulatory approval.
• Exceeding optimal concentration may induce cytotoxicity in non-cardiac cell types.

For an analytical perspective on mechanistic boundaries and optimization, see this recent article, which this dossier updates with new antiviral benchmarking data and workflow integration strategies.

Workflow Integration & Parameters

Digoxin (SKU: B7684) is supplied as a solid by APExBIO, with a documented purity of >98.6%. It is soluble at concentrations ≥33.25 mg/mL in DMSO, but insoluble in water and ethanol. Solutions should be prepared fresh and used promptly for maximal activity. Storage is recommended at room temperature in dry conditions. In vitro antiviral protocols typically use 0.01–10 μM digoxin, while animal studies may use intravenous doses of 1–1.2 mg, depending on the model and endpoint. Quality control is supported by HPLC, NMR, and MSDS documentation (Digoxin product page). For detailed protocols and validated use cases, consult this protocol guide. This article updates the guide with direct benchmarks for CHIKV inhibition and solubility management.

Conclusion & Outlook

Digoxin remains a cornerstone tool in cardiovascular and antiviral research. Its precise mechanism as a Na⁺/K⁺-ATPase pump inhibitor is well-characterized, with robust efficacy in both cardiac and infectious disease models. APExBIO’s high-purity Digoxin (SKU: B7684) enables sensitive, reproducible, and safe experimental workflows across diverse research disciplines. Future studies may further elucidate digoxin’s roles in multi-pathway modulation and expand its antiviral applications. Researchers are encouraged to consult the official product page for updated documentation and QC support.